7 Top Gainers In Healthcare Sector (PTX, MYOV, DXR...)

Pernix Therapeutics Holdings is the parent company of Pernix Therapeutics LLC, a specialty pharmaceutical business focused on acquiring and commercializing prescription drugs, primarily for the U.S. market.

Gained 54.24% to close Wednesday's (Feb.13) trading at $1.82.

News: No news

Recent event:

On November 8, 2018, the Company reported third-quarter financial results.

Net loss was $11.8 million or $0.89 per share for the three months ended September 30, 2018, compared to net income of $6.4 million or $0.42 per share in the same period last year. Net revenues were $37.2 million for the third quarter of 2018, an 8% decrease from the $40.5 million in the third quarter of 2017.

The Company ended September 30, 2018, with cash and cash equivalents of $24.5 million.

BIOLASE is a biomedical company developing dental lasers and dental imaging equipment.

Gained 25% to close Wednesday's trading at $2.25.

News: No news

Near-term Catalyst:

-- The Company is scheduled to release fourth quarter 2018 financial and operating results on March 5, 2019.

Net revenue for the third quarter of 2018 was $10.9 million, a slight increase from net revenue of $10.8 million in the year-ago same quarter. Net loss was $4.66 million or $0.23 per share in the third quarter of 2018 compared to a net loss of $4.61 million or $0.30 per share in the third quarter of 2017.

-- A phase II trial of CPI-0610 in myelofibrosis, dubbed MANIFEST, is ongoing. interim data update of this trial is expected in Q2, 2019.-- A phase Ib/II trial of CPI-1205 in metastatic castration-resistant prostate cancer (mCRPC) in combination with either abiraterone or enzalutamide, dubbed ProSTAR, is underway. Data from phase Ib portion of the trial is anticipated in Q2, 2019, and interim phase II data of the ProSTAR trial is expected in the second half of 2019.-- A phase I study of CPI-0209 in solid tumors is expected to be initiated in mid-2019.

Also in the pipeline is MVT-602, for the treatment of female infertility as part of assisted reproduction. This compound is under Phase 2a study in healthy women undergoing a controlled ovarian stimulation protocol.

Near-term Catalysts:

-- Top-line data from LIBERTY 1 phase III study is expected in Q2, 2019.-- Top-line results from phase IIa study of MVT-602 are expected to be reported in the first half of 2019.-- Top-line data from LIBERTY 2 phase III study is expected in Q3, 2019.-- Top-line data from HERO phase III study is expected in Q4, 2019.-- Enrollment in both SPIRIT 1 and SPIRIT 2 phase III trials is expected to be completed in Q1 2020.

The Company manufactures and markets FDA-cleared BVA-100 blood volume analyzer, which is used in conjunction with a single-use diagnostic kit.

Gained 11.71% to close Wednesday's trading at $18.99.

News: The Company will be sharing new data and how the BVA-100 can help guide fluid management to enhance treatment plans and individualize care at the Society for Critical Care Medicine (SCCM) 48th Congress at the San Diego Convention Center in San Diego, CA from February 17-19th, 2019.

New data published in the Journal of the American College of Cardiology - Heart Failure last October showed a reduction of 82% mortality and 56% reduced 30-day readmission rehospitalization in patients who received individualized treatment for acute heart failure guided by Daxor's BVA-100 Blood Volume Analyzer.